Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake
Executive Summary
Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.
You may also be interested in...
FDA Publishes BsUFA III Commitment Letter Ahead Of 2022 Renewal
Following months of negotiations with industry and stakeholders, the FDA has released the commitment letter for the third iteration of its five-year Biosimilar User Fee Amendments program, marking another step ahead of its reauthorization.
BsUFA III Expands Biosimilar Supplement Review Goals To Speed Approvals
Six supplement categories based on submission content will be created with review goals between three and 10 months.
FDA Official Foresees Reduced Biosimilar Data Burden
New guidance from UK's MHRA saying comparative clinical efficacy studies typically will not be needed is a start, but other regulators may need a few years before adopting similar rules.